Combined targeting of VISTA and sorafenib activates T cell-mediated anti-tumor immunity via the NF-κB/TNF axis in hepatocellular carcinoma.

In parallel, VISTA co-expression with CD3 was also significantly elevated compared with the control and anti-VISTA antibody groups, although this difference did not reach statistical significance relative to the sorafenib monotherapy group (Fig. 5 B).

also in 111,027 other papers